Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok

Arch Biopartners (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro-Technics in Scarborough, Ontario to complete the preclinical toxicology and pharmacology studies to support an Investigational New Drug (IND) application for Metablok, the Company’s drug candidate for preventing acute kidney injury.

As quoted in the press release:

Specifically, Nucro-Technics will be performing the good laboratory practice (GLP) toxicology and pharmacology studies previously confirmed by the U.S. Food and Drug Administration (FDA) during the pre-IND meeting with the Company on April 18, 2018.

Arch is preparing an IND application and a Phase I human trial to evaluate Metablok’s safety and pharmacokinetic profile in advance of future clinical trials to test its efficacy in treating or preventing cardiac surgery-associated acute kidney injury.

Nucro-Technics looks forward to continuing to advance Arch Biopartners drug candidate Metablok through to clinical stages. “We are pleased to support Arch Biopartners upcoming IND application for Metablok by performing the required toxicology and pharmacology studies,” said John C. Fanaras, President of Nucro-Technics.

Click here to read the full press release.